Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Small Cell Lung Carcinoma 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasms by Histologic Type 1Neoplasms 1Multiple Myeloma 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Peripheral 1Lymphoma 1Lymphatic Diseases 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms, Male 1

Interventions

tetulomab tetraxetan lu-177 2fludarabine 2dacetuzumab 2Lutetium 2Bendamustine Hydrochloride 2fludarabine phosphate 1ficlatuzumab 1denileukin diftitox 1Rituximab 1Lutetium-177 1Gemcitabine 1Erlotinib Hydrochloride 1Cyclophosphamide 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphatic Diseases × denileukin diftitox × Clear all
NCT01401530 2018-11-23

E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma

Eisai Inc.

Phase 1 Completed
13 enrolled 18 charts
Lymphoid

Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡